Tenet Healthcare (THC) Stock Moves -0.39%: What You Should Know

Tenet Healthcare (THC) ended the recent trading session at $120.44, demonstrating a -0.39% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 2.24%. Meanwhile, the Dow lost 1.73%, and the Nasdaq, a tech-heavy index, lost 3.07%.Prior to today's trading, shares of the hospital operator had lost 3.53% over the past month. This has was narrower than the Medical sector's loss of 7.47% and the S&P 500's loss of 4.17% in that time.The upcoming earnings release of Tenet Healthcare will be of great interest to investors. The company's earnings report is expected on April 29, 2025. The company is expected to report EPS of $3.12, down 3.11% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.17 billion, down 3.66% from the year-ago period.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.15 per share and a revenue of $20.88 billion, indicating changes of +2.27% and +1.06%, respectively, from the former year.Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Tenet Healthcare. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.37% higher within the past month. Tenet Healthcare is currently sporting a Zacks Rank of #3 (Hold).In terms of valuation, Tenet Healthcare is currently trading at a Forward P/E ratio of 9.95. Its industry sports an average Forward P/E of 9.61, so one might conclude that Tenet Healthcare is trading at a premium comparatively.It's also important to note that THC currently trades at a PEG ratio of 0.91. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Hospital industry held an average PEG ratio of 1.03.The Medical - Hospital industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 43, positioning it in the top 18% of all 250+ industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks